Skip to content
CompletedNot applicable

Dance Movement Therapy for Radio-oncological Patients

NCT07001033 · DANCE-RT-01 · University of Erlangen-Nürnberg Medical School

Closed to entry
Status
Not accepting participants
Not applicable
Phase
8
Target enrolment
1
Study sites
Outside the US

What it is testing

Summary

Dance-RT-01 investigates the feasibility and effects of Integrative, resource-oriented short term Dance Movement Therapy (DMT) in radio-oncological patients shortly after radiotherapy (RT). The study assesses clinical outcomes, including reduction of fatigue, improvement of quality of life (QoL), functional capacity and body composition. Immunophenotyping and laboratory blood analyses ensure objectively measurable results. Eligible patients participate in short term DMT, that is combined with psychotherapeutic elements. The trial aims to evaluate DMT's potential as a complementary therapy method in cancer care to support recovery and provide a comprehensive understanding of the therapy's effects.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Primary objective

    Measured over in the week 1 (baseline) in the week 3, in the week 5 (end of study)

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Male and female oncological patients * Age at least 18 years. No upper age limit * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Written informed consent for participation in the study * Prior RT received shortly before study inclusion (therapy completed) * Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including Exclusion Criteria: * Inability to speak and understand German * Serious concurrent neurologic or psychiatric disorders: dementia, uncontrolled seizures, psychosis, schizophrenia, neurosis, autism that would interfere with cooperation with the requirements of the trial * Familial, sociological, or geographical condition that would preclude study compliance (these conditions should be discussed with the patient before registration in the study) * Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the study team * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial * Is pregnant or breastfeeding, or expecting to conceive

Where

1 study site

FacilityCityRegionCountry
Department of Radiation Oncology, Translational Radiobiology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-NürnbergErlangenBavariaGermany

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT07001033 on ClinicalTrials.gov →

Last updated in the registry 2025-06-03. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits

Substance